What is Freespira?
Freespira offers an FDA-cleared, non-invasive, and drug-free four-week at-home treatment for panic attacks and panic symptoms, administered under the supervision of a licensed healthcare provider. The treatment is clinically validated to reduce or eliminate panic attacks and associated symptoms of panic disorder, a condition characterized by debilitating anxiety leading to significant avoidance behaviors. Freespira's core mechanism involves training patients to stabilize their respiration rate and exhaled carbon dioxide levels, addressing chronic hyperventilation which is often linked to the onset or exacerbation of panic attacks. This approach represents a significant advancement in accessible and effective mental health care.
How much funding has Freespira raised?
Freespira has raised a total of $10M across 1 funding round:
Unspecified
$10M
Unspecified (2020): $10M with participation from Lightspeed Venture Partners, Medvest Capital, and Aphelion Capital LLC
Key Investors in Freespira
Lightspeed Venture Partners
Lightspeed Venture Partners (lsvp.com) is a global multistage venture capital firm that invests in early and growth-stage technology companies across various sectors, including enterprise software and healthcare, partnering with founders from seed through IPO/M&A.
Medvest Capital
Medvest Capital is a venture capital firm established in 2013 that specializes in investing in early-stage medical device companies, aiming to improve patient outcomes and accelerate product development.
Aphelion Capital LLC
Undisclosed investor participating in the funding round.
What's next for Freespira?
The substantial enterprise-level funding and recent strategic investment signal a pivotal growth phase for Freespira. This capital infusion is expected to accelerate market penetration, further clinical validation, and potentially expand the company's treatment offerings or geographic reach. The focus on a drug-free, non-invasive solution positions Freespira to capture a significant share of the mental wellness market, particularly among individuals seeking alternatives to traditional pharmaceutical interventions. Future developments may include broader integration with healthcare systems and enhanced digital support for patients and providers.
See full Freespira company page
